Prognostic contribution of predicted sensitivity to endocrine therapy (SET) prior to neoadjuvant chemotherapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer

被引：0
|
作者：
Du, Lili [1 ]
Yau, Christina [2 ]
Brown-Swigart, Lamorna [2 ]
Gould, Rebekah [1 ]
Hirst, Gillian L. [2 ]
van der Noordaa, Marieke [2 ]
Bedrosian, Isabelle [1 ]
Layman, Rachel M. [1 ]
Valero, Vicente [1 ]
Van't Veer, Laura [2 ]
Esserman, Laura [2 ]
Symmans, W. Fraser [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P2-11-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-11-04
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy
    Du, L.
    Yau, C.
    Brown-Swigart, L.
    Gould, R.
    Krings, G.
    Hirst, G. L.
    Bedrosian, I
    Layman, R. M.
    Carter, J. M.
    Klein, M.
    Venters, S.
    Shad, S.
    van der Noordaa, M.
    Chien, A. J.
    Haddad, T.
    Isaacs, C.
    Pusztai, L.
    Albain, K.
    Nanda, R.
    Tripathy, D.
    Liu, M. C.
    Boughey, J.
    Schwab, R.
    Hylton, N.
    DeMichele, A.
    Perlmutter, J.
    Yee, D.
    Berry, D.
    van't Veer, L.
    Valero, V.
    Esserman, L. J.
    Symmans, W. F.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (05) : 642 - 651
  • [2] Ribociclib (RIB) plus endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)
    Masuda, N.
    Noguchi, S.
    Ishikawa, T.
    Aruga, T.
    Kim, S. J.
    Toyama, T.
    Saeki, T.
    Saito, M.
    Yamanaka, T.
    Watanabe, J.
    Nakamura, S.
    Takahashi, M.
    Inoue, K.
    Gounaris, I.
    Han, Y.
    Samant, T. S.
    Gazdoiu, M.
    Ito, Y.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [3] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
  • [4] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    [J]. CANCER TREATMENT REVIEWS, 2024, 123
  • [5] Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity
    Frassoldati, Antonio
    Biganzoli, Laura
    Bordonaro, Roberto
    Cinieri, Saverio
    Conte, Pierfranco
    De Laurentis, Michelino
    Del Mastro, Lucia
    Gori, Stefania
    Lauria, Rossella
    Marchetti, Paolo
    Michelotti, Andrea
    Montemurro, Filippo
    Naso, Giuseppe
    Pronzato, Paolo
    Puglisi, Fabio
    Tondini, Carlo Alberto
    [J]. FUTURE ONCOLOGY, 2020, 16 (05) : 129 - 145
  • [6] Development and validation of RSClin N plus tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer
    Pusztai, Lajos
    Hoag, Jess R.
    Albain, Kathy S.
    Barlow, William E.
    Stemmer, Salomon M.
    Meisner, Allison
    Hortobagyi, Gabriel N.
    Shak, Steven
    Hayes, Daniel F.
    Rae, James M.
    Baehner, Frederick
    Sharma, Priyanka
    Kalinsky, Kevin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Clinical and molecular impact of neoadjuvant chemotherapy (NACT) or endocrine therapy (NET) on hormone receptor positive (HR+)/HER2-negative (-) breast cancer (BC)
    Schettini, F.
    Braso-Maristany, F.
    Pascual, T.
    Galvan, P.
    Conte, B.
    Ghiglione, L.
    Falato, C.
    Martinez-Saez, O.
    Chic, N.
    Rodriguez, A. B.
    Torres, E. Sanfeliu
    Gonzalez-Farre, B.
    Losada, M. J. Vidal
    Adamo, B.
    Cebrecos, I.
    Mension, E.
    Oses, G.
    Molla, M.
    Munoz, M.
    Prat, A.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S294 - S294
  • [8] Neoadjuvant tucidinostat combined with chemotherapy for hormone receptor-positive, HER2-negative breast cancer
    Niu, Nan
    Xue, Jinqi
    Qiu, Fang
    Chen, Guanglei
    Gu, Xi
    He, Guijin
    Cao, Shuo
    Yu, Xiaopeng
    Xu, Yongqing
    Yin, Jianqiao
    Han, Sijia
    Han, Ye
    Tang, Meiyue
    Zhao, Yafei
    Zheng, Ran
    Zheng, Xinyu
    Xu, Hong
    Liu, Caigang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) receiving ribociclib (RIB) plus endocrine therapy (ET)
    Yap, Y. S.
    Masuda, N.
    Ito, Y.
    Ishikawa, T.
    Kim, S. J.
    Aruga, T.
    Toyama, T.
    Saeki, T.
    Yamanaka, T.
    Saito, M.
    Watanabe, J.
    Takahashi, M.
    Nakamura, S.
    Inoue, K.
    Suarez-Vizcarra, J.
    He, W.
    Solovieff, N.
    Su, F.
    Chiu, J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 13 - +
  • [10] Blinded independent validation of the PAM50-based Chemo-Endocrine Sensitivity Predictor (CESP) in hormone receptor (HR)-positive/HER2-negative (HR+/HER2-) breast cancer following neoadjuvant chemotherapy (NAC).
    Prat, Aleix
    Jimenez Rodriguez, Begona
    Sanchez Rovira, Pedro
    Alvarez, Martina
    Vicioso, Luis
    de Luque, Vanessa
    Fernandez-Sousa, Cristina
    Chica Parrado, M. Rosario
    Santonja, Angela
    Ramirez Tortosa, Cesar
    Lavado Fernandez, Ana Isabel
    Perez Ruiz, Elisabeth
    Gonzalez-Hermoso, Carlos
    Buckingham, Wesley
    Dowidar, Naeem
    Ferree, Sean
    Jeiranian, Arthur
    Schaper, Carl
    Ribelles, Nuria
    Alba, Emilio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345